Pamorelin (Triptorelin)

Triptorelin, the active ingredient in Pamorelin, is a Gonadotropin-releasing hormone (GnRH) agonist presented as a strength/form for injection use. It is employed in hormone therapy for conditions such as prostate cancer, endometriosis, and assisted reproductive technology protocols. GNH USA supplies Pamorelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Pamorelin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamorelin is a GnRH agonist that modulates the hormonal axis involved in several endocrine‑related conditions.

- Prostate cancer: provides androgen suppression to slow tumor growth. - Endometriosis: reduces estrogen production to alleviate pelvic pain and lesion progression. - Assisted reproductive technology: controls ovarian stimulation timing during IVF cycles. - Precocious puberty: delays early onset of secondary sexual characteristics. - Uterine fibroids: decreases hormone‑driven fibroid growth. - Hormone‑dependent breast cancer: contributes to estrogen suppression as part of combination therapy.

Side effects vary with the degree of hormonal suppression and individual patient factors.

Common Side Effects: - Hot flashes - Headache - Injection site pain - Mood changes - Decreased libido - Fatigue

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Cardiovascular events such as myocardial infarction - Bone density loss leading to osteoporosis - Liver function abnormalities - Pituitary apoplexy (very rare) - Severe depression or suicidal ideation

When prescribing Pamorelin, clinicians should consider several safety aspects.

- Cardiac monitoring: patients with existing heart disease may need regular ECGs. - Bone health: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Liver function: evaluate baseline hepatic enzymes and monitor periodically. - Pregnancy and lactation: avoid use in women who are pregnant or breastfeeding. - Drug interactions: review concomitant medications for potential hormonal effects. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Triptorelin may interact with other agents that influence hormonal pathways or cardiovascular status.

Major Interactions (Avoid): - Combined androgen blockade therapies: may amplify hormonal suppression and cardiovascular strain. - Long‑acting estrogen preparations: can increase risk of thromboembolic events.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor coagulation parameters due to altered estrogen levels. - CYP450‑modulating drugs: may affect metabolism of concomitant hormonal agents. - Steroid hormones (e.g., corticosteroids): adjust dosing if significant hormonal fluctuations occur. - Antidepressants: observe for mood changes that could be compounded by hormonal shifts. - Herbal supplements such as St ").